Literature DB >> 12411462

Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance.

.   

Abstract

The association of insulin resistance and hyperinsulinemia to blood pressure has remained controversial. We examined the association of insulinemia to hypertension and blood pressure using baseline measurements for participants of the Diabetes Prevention Program (DPP). The DPP is a multicenter randomized controlled trial of 3819 participants with impaired glucose tolerance, and is designed to evaluate interventions for the delay or prevention of type 2 diabetes. The relationship between hypertension and insulinemia is described overall and by ethnicity. The effects of demographics (age and gender), adiposity, and glucose on the relationship are also presented. Asian Americans and African Americans had a similarly high prevalence of hypertension as did whites; American Indians had a lower prevalence of hypertension. Among participants not on antihypertensive medications, systolic blood pressure was significantly (but weakly) correlated with fasting insulin (r=0.12), homeostasis model assessment of insulin resistance (HOMA IR; r=0.13), and fasting proinsulin (r=0.10) when adjusted for age and gender (all, P<0.001). Systolic blood pressure showed similar correlations to fasting insulin in each ethnic group. After further adjustment for body mass index, the association of fasting insulin to systolic and diastolic blood pressures weakened considerably but remained significant (systolic: r=0.06, P=0.002; DBP: r=0.06, P<0.001). We conclude that a weak but significant association between insulin, (and proinsulin and HOMA IR) and blood pressure exists but is largely explained by overall adiposity. This association is similar among ethnicities, with the possible exception of Hispanics. The relation between insulin concentrations and blood pressure explains relatively little of the ethnic differences in hypertensive prevalence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411462      PMCID: PMC2516377          DOI: 10.1161/01.hyp.0000035706.28494.09

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  58 in total

Review 1.  Racial differences in ion regulation and their possible links to hypertension in blacks.

Authors:  A Aviv; J Gardner
Journal:  Hypertension       Date:  1989-12       Impact factor: 10.190

2.  Insulin resistance is a characteristic feature of primary hypertension independent of obesity.

Authors:  T Pollare; H Lithell; C Berne
Journal:  Metabolism       Date:  1990-02       Impact factor: 8.694

Review 3.  Effects of insulin upon ion transport.

Authors:  R D Moore
Journal:  Biochim Biophys Acta       Date:  1983-03-21

4.  Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance.

Authors:  M Laakso; S V Edelman; G Brechtel; A D Baron
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

5.  Reduced postprandial skeletal muscle blood flow contributes to glucose intolerance in human obesity.

Authors:  A D Baron; M Laakso; G Brechtel; B Hoit; C Watt; S V Edelman
Journal:  J Clin Endocrinol Metab       Date:  1990-06       Impact factor: 5.958

6.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

7.  Essential hypertension and insulin resistance in non-insulin-dependent diabetes.

Authors:  M Laakso; H Sarlund; L Mykkänen
Journal:  Eur J Clin Invest       Date:  1989-12       Impact factor: 4.686

8.  Abnormal glucose tolerance and hypertension.

Authors:  P D Reaven; E L Barrett-Connor; D K Browner
Journal:  Diabetes Care       Date:  1990-02       Impact factor: 19.112

9.  Hyperinsulinemia. A link between hypertension obesity and glucose intolerance.

Authors:  M Modan; H Halkin; S Almog; A Lusky; A Eshkol; M Shefi; A Shitrit; Z Fuchs
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

10.  Plasma insulin and lipoprotein concentrations: an atherogenic association?

Authors:  T J Orchard; D J Becker; M Bates; L H Kuller; A L Drash
Journal:  Am J Epidemiol       Date:  1983-09       Impact factor: 4.897

View more
  17 in total

1.  Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program.

Authors: 
Journal:  Diabetes Care       Date:  2005-10       Impact factor: 19.112

Review 2.  Behavioral strategies for cardiovascular risk reduction in diverse and underserved racial/ethnic groups.

Authors:  Eileen M Stuart-Shor; Kathy A Berra; Mercy W Kamau; Shiriki K Kumanyika
Journal:  Circulation       Date:  2012-01-03       Impact factor: 29.690

3.  Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.

Authors:  Robert Ratner; Ronald Goldberg; Steven Haffner; Santica Marcovina; Trevor Orchard; Sarah Fowler; Marinella Temprosa
Journal:  Diabetes Care       Date:  2005-04       Impact factor: 19.112

Review 4.  Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.

Authors:  Ronald B Goldberg; Kieren Mather
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09       Impact factor: 8.311

5.  Reducing metabolic syndrome through a community-based lifestyle intervention in African American women.

Authors:  Abdullah Mamun; Heather Kitzman; Leilani Dodgen
Journal:  Nutr Metab Cardiovasc Dis       Date:  2020-06-12       Impact factor: 4.222

6.  Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome.

Authors:  Melvin R Hayden; James R Sowers
Journal:  J Am Soc Hypertens       Date:  2008-06-02

7.  Evaluating the accuracy of an aneroid sphygmomanometer in a clinical trial setting.

Authors:  Yong Ma; Marinella Temprosa; Sarah Fowler; Ronald J Prineas; Maria G Montez; Janet Brown-Friday; Mary L Carrion-Petersen; Tracy Whittington
Journal:  Am J Hypertens       Date:  2008-12-04       Impact factor: 2.689

Review 8.  Angiotensin II type 1 receptor polymorphisms and susceptibility to hypertension: a HuGE review.

Authors:  Amy K Mottl; David A Shoham; Kari E North
Journal:  Genet Med       Date:  2008-08       Impact factor: 8.822

9.  Metabolic syndrome in South Asians.

Authors:  Kaushik Pandit; Soumik Goswami; Sujoy Ghosh; Pradip Mukhopadhyay; Subhankar Chowdhury
Journal:  Indian J Endocrinol Metab       Date:  2012-01

10.  Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin in patients with mild to moderate hypertension.

Authors:  Weon Kim; Myong Joo Hong; Jong Shin Woo; Won Yu Kang; Sun Ho Hwang; Wan Kim
Journal:  Chonnam Med J       Date:  2013-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.